HI
SABS icon

Harbour Investments’s SAB Biotherapeutics SABS Stock Holding History

Harbour Investments’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195 Hold
50
– – ﹤0.01% 4551
2026
Q1 		$192 Hold
50
– – ﹤0.01% 4442
2025
Q4 		$187 Hold
50
– – ﹤0.01% 3684
2025
Q3 		$101 Hold
50
– – ﹤0.01% 3644
2025
Q2 		$88 Hold
50
– – ﹤0.01% 3522
2025
Q1 		$68 Hold
50
– – ﹤0.01% 3492
2024
Q4 		$190 Hold
50
– – ﹤0.01% 3372
2024
Q3 		$135 Hold
50
– – ﹤0.01% 3302
2024
Q2 		$155 Hold
50
– – ﹤0.01% 3183
2024
Q1 		$227 Buy
+50
New +$275 ﹤0.01% 3105
2023
Q4 		– Sell
-50
Closed -$315 – 3184
2023
Q3 		$315 Hold
50
– – ﹤0.01% 2849
2023
Q2 		$415 Hold
50
– – ﹤0.01% 2839
2023
Q1 		$220 Buy
+50
New +$316 ﹤0.01% 2866

Other funds holding SABS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Harbour Investments's SABS Position: Q2 2026 in Review

Harbour Investments held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 50 shares worth $195. The position accounts for ﹤0.01% of the portfolio, ranked #4551.

Harbour Investments first reported a position in SABS in Q1 2023 and has held it in 13 quarters since. The position peaked at $415 in Q2 2023. 49 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Harbour Investments held 50 shares of SAB Biotherapeutics worth $195 as of Q2 2026.
  • Harbour Investments left its SAB Biotherapeutics share count unchanged in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4551 holding.
  • Harbour Investments first reported a position in SAB Biotherapeutics in Q1 2023 and has held it in 13 quarters since.
  • Harbour Investments's SAB Biotherapeutics position peaked at $415 in Q2 2023.
  • 49 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.